President Biden to Sign Executive Order Seeking New Prescription Drug Cost Savings
-Reuters Citing Official
https://www.reuters.com/world/us/biden-sign-order-seeking-new-prescription-drug-cost-savings-official-2022-10-14/
AstraZeneca Unit Alexion Said Aims to Advance NMOSD Treatment Landscape with Exceptional Ultomiris Efficacy data at ECTRIMS 2022
Alexion, AstraZeneca Rare Disease, will present new data showing significant advances for the treatment of anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, 26 to 28 October 2022.
Illumina Inks AI Pact With AstraZeneca To Accelerate Drug Target Discovery
Illumina Inc (NASDAQ:ILMN) entered a strategic research collaboration with AstraZeneca plc (NASDAQ:AZN) on drug target discovery. Financial and other details of the partnership…
AstraZeneca’s COVID Vaccine Suffers a Setback in Nasal Spray Trial; Did Not Yield Desired Protection
-Reuters
https://www.reuters.com/business/healthcare-pharmaceuticals/astrazenecas-covid-vaccine-suffers-setback-nasal-spray-trial-2022-10-10/
Honeywell Begins Production Of Near-Zero Global-Warming-Potential Medical Propellant
Honeywell Solstice® Air (HFO-1234ze(E) cGMP) to be used in next-generation respiratory inhalers from AstraZeneca
Why LogicBio Therapeutics Stock Is Soaring Today
LogicBio Therapeutics Inc (NASDAQ: LOGC) shares are trading higher Monday after the company announced it will be acquired by AstraZeneca PLC (NASDAQ: AZN) subsidiary Alexion for $2.07 per share.
Why Are LogicBio Therapeutics Shares Skyrocketing Today?
AstraZeneca Plc’s (NASDAQ:AZN) subsidiary, Alexion, has agreed to acquire LogicBio Therapeutics Inc (NASDAQ:LOGC) for $2.07 per share. Both boards have unanimously approved…
AstraZeneca-Merck’s Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October’s Key PDUFA Catalysts Biotech Investors Must Know
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the total NME approvals for the year to 24. This is far less than the 40 approvals received by the same time last year.
-Japan Ends Astrazeneca Covid-19 Vaccine Rollout As Contract Expires
-Reuters Citing Japan Health Ministry